In clinical practice, individualized drug regimens need to be developed based on patient-specific conditions, and therapeutic drug monitoring and individualized genetic testing are effective tools to increase the efficacy and decrease the adverse effects of metformin for PCOS therapy
Furthermore, it is anticipated that the GLP-1 receptor agonist cardiovascular therapy market will develop due to ongoing advancements in medication formulations and administration methods, such as long-acting injectables and oral treatments
Sessions are recommended 4 weeks apart
41 ChengF.VivacquaG.YuS
doi: 10.3389/fendo.2026.1811207 Received 14 February 2026 Revised 14 April 2026 Accepted 20 April 2026 Published 01 May 2026 Volume 17 - 2026 Edited by Pradip Sarkar, Parker University, United States Reviewed by Stefano Guandalini, The University of Chicago, United States Dante Pio Pallotta, University of Bologna, Italy Updates Copyright 2026 Fan, Li, Fan and Fan